Dalhousie Myeloma Research Group

Our mission

To channel the skills of a uniquely diverse group of experts to offer world class advancement in multiple myeloma research through translational science and integrated approaches.

Team members


  • Establish & maintain a viable Myeloma Tumor Bank & Database (MTBD)
  • Establish a genetic panel to assess MM during progression and treatment
  • Identify epigenetic signatures that define high risk of disease progression
  • Understand how genetic mutations in MM can predict interactions with the immune system to guide therapy
  • Develop NK cell-based immunotherapy for precision medicine against MM
  • Improve access to cutting-edge research for Atlantic Canadians to improve treatment options and efficacy

Methods & Technologies

Tumour genomics (Illumina) - epigenetics (Illumina; ChIP-Seq) - transcriptomics (Illumina, qPCR) - Immunogenomics (PCR, sequencing, SSO) - Immunology (model systems: flow cytometry, in vitro stimulations, humanized mice, human lymphocytes, CRISPR-Cas9), mass-spectrometry-based proteomics, and immune-metabolomics, in vivo animal modelling and preclinical testing, MHC ligandomics and high throughput tumor epitope discovery 

Funding Sources


  • NSHRF: for Myeloma Tumor Bank and genomic work
  • NSHRF: for continuing the genomic work on our biobanked myeloma samples
  • CCSRI: Innate immune evasion by the cancers of the blood and breast
  • NSHRF: The role of natural killer cell and its MHC-I receptors in the regulation of anti-cancer immune responses mediated by T cells
  • BHCRI: Role of NAD+ synthesizing enzyme NMNAT3 in cancer biology
  • CRS: Proline Regulatory Axis in cancer cell metabolism
  • NIH: Photodynamic therapy-induced immunogenic cell death to promote antitumor immunity